GlassScriptPhysician profile
Marvin D Rodgers
NPI 1023090610
$8,680.80
in general payments reported to CMS, 2019-2025
52 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,222 · 2020: $1,092 · 2021: $1,513 · 2022: $1,464 · 2023: $1,225 · 2024: $895 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,389.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,340.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,049.29 | 2019-2025 | Vraylar, Ubrelvy, Botox |
| Astrazeneca Pharmaceuticals LP | $735.90 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $714.21 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $548.62 | 2019-2025 | Belsomra, Enflonsia, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $522.77 | 2019-2025 | Trintellix |
| Pfizer INC. | $507.16 | 2019-2025 | |
| Amgen INC. | $381.27 | 2019-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.89 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $170.15 | 2019-2022 | |
| Amarin Pharma, INC. | $167.10 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.87 | 2021-2025 | |
| Glaxosmithkline, LLC. | $150.43 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.66 | 2025 | Caplyta |
| Antares Pharma, INC. | $125.66 | 2020-2025 | Xyosted |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Rodgers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.